A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Cancers|Non-Hodgkin's Lymphoma
Interventions: DRUG: Fulvestrant|DRUG: GDC-0032|DRUG: Letrozole|DRUG: Midazolam
Sponsor: Genentech, Inc.